AGN up after releasing additional results from study Algernon Pharmaceuticals Inc. (AGN.c) is trading in the green after announcing additional results from its Phase 2a Study of its Ifenprodil drug for idiopathic pulmonary fibrosis and chronic cough.
Upon further review, Ifenprodil was shown to be much more effective at reducing coughing than initially reported, showing that patients had significant improvement in 24-hour and waking cough counts after 4 and 12 weeks.
These new findings were found by looking at geometric means rather than arithmetic means (a preferred way to look at data when it is not normally distributed)
Looking at the geometric mean:
- 24-hour cough counts were reduced by 32.0% at 4 weeks and 39.5% at 12 weeks compared to baseline
- Awake cough counts were reduced by 30.2% at 4 weeks and 37.4% at 12 weeks compared to baseline
More here:
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-reports-additional-positive-110000418.html